In-Depth Insights: 6 Analysts Weigh In on ACADIA Pharmaceuticals Stock
Analyst Ratings Overview: In the last three months, 6 analysts have provided ratings for ACADIA Pharmaceuticals, with a mix of bullish and bearish sentiments, resulting in a total of 5 bullish and 1 somewhat bullish ratings in the last 30 days.
Price Target Insights: Analysts have set an average 12-month price target of $33.5 for ACADIA Pharmaceuticals, with a high estimate of $39.00 and a low of $28.00, reflecting a slight increase from the previous average of $32.60.
Company Background: ACADIA Pharmaceuticals focuses on developing treatments for central nervous system disorders and rare diseases, with key products including NUPLAZID for Parkinson's Disease Psychosis and DAYBUE for Rett syndrome.
Financial Performance Indicators: The company shows strong financial health with a net margin of 10.08%, a return on equity of 3.36%, and a debt-to-equity ratio of 0.07, indicating effective cost management and a solid financial structure.
Trade with 70% Backtested Accuracy
Analyst Views on ACAD
About ACAD
About the author

Acadia Pharmaceuticals to Present at 2026 J.P. Morgan Healthcare Conference
- Conference Participation: Acadia Pharmaceuticals will be represented by CEO Catherine Owen Adams at the J.P. Morgan Healthcare Conference on January 13, 2026, showcasing its innovations in neurological diseases, which is expected to attract investor interest.
- Live Webcast: The presentation will be accessible via a live webcast on Acadia's website, allowing global investors to stay updated on the company's latest developments, with an archived recording available for one month post-event to enhance transparency and investor relations.
- Product Portfolio: Acadia is committed to providing FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome, demonstrating its leadership in the neurological disease sector, which may draw increased attention and investment in the future.
- R&D Pipeline: The company is developing mid- to late-stage programs targeting Alzheimer's disease psychosis and Lewy body dementia, indicating its strategic commitment to addressing underserved patient needs, potentially driving future market growth.

Acadia Receives FDA Approval for DAYBUE STIX Treatment of Rett Syndrome
- New Drug Approval: Acadia Pharmaceuticals announced that the FDA has approved DAYBUE STIX (trofinetide) for the treatment of Rett syndrome, making it the only FDA-approved treatment, expected to provide new options for 6,000 to 9,000 patients in the U.S.
- Flexible Formulation: DAYBUE STIX features a dye- and preservative-free powder formulation that allows patients to customize dosage and taste, enhancing the medication experience for patients and caregivers and addressing the urgent need for flexibility among families.
- Clinical Validation: The efficacy and safety of the new formulation are based on results from the LAVENDER™ study, demonstrating bioequivalence to the original oral solution, ensuring that patients can expect the same therapeutic effects when using the new formulation, further solidifying Acadia's leadership in the neurological disease space.
- Market Outlook: DAYBUE STIX is expected to launch on a limited basis in Q1 2026 and more broadly in Q2 2026, marking Acadia's ongoing commitment to meet the needs of Rett syndrome patients while laying the groundwork for future revenue growth.






